Co-Authors
This is a "connection" page, showing publications co-authored by AMIR A JAZAERI and PATRICK HWU.
Connection Strength
1.127
-
Efficacy and safety of autologous tumor-infiltrating lymphocytes in recurrent or refractory ovarian cancer, colorectal cancer, and pancreatic ductal adenocarcinoma. J Immunother Cancer. 2024 Feb 02; 12(2).
Score: 0.243
-
Toxicity and efficacy of the combination of pembrolizumab with recommended or reduced starting doses of lenvatinib for treatment of recurrent endometrial cancer. Gynecol Oncol. 2021 07; 162(1):24-31.
Score: 0.201
-
Applications of CRISPR Genome Editing to Advance the Next Generation of Adoptive Cell Therapies for Cancer. Cancer Discov. 2021 03; 11(3):560-574.
Score: 0.198
-
Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. Cancer Immunol Immunother. 2019 Sep; 68(9):1515-1526.
Score: 0.179
-
Characteristics and outcomes of patients with recurrent ovarian cancer undergoing early phase immune checkpoint inhibitor clinical trials. Gynecol Oncol. 2018 12; 151(3):407-413.
Score: 0.169
-
CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-? signaling. J Immunother Cancer. 2022 07; 10(7).
Score: 0.054
-
Potential clinical application of tumor-infiltrating lymphocyte therapy for ovarian epithelial cancer prior or post-resistance to chemotherapy. Cancer Immunol Immunother. 2019 Nov; 68(11):1747-1757.
Score: 0.045
-
Cervical Cancer Neoantigen Landscape and Immune Activity is Associated with Human Papillomavirus Master Regulators. Front Immunol. 2017; 8:689.
Score: 0.038